Five Health Conditions Linked to Subsequent Diagnosis of MS
By Elana Gotkine HealthDay Reporter
TUESDAY, Dec. 5, 2023 -- Five health conditions are associated with subsequent diagnosis of multiple sclerosis, but they overlap with two other autoimmune diseases, according to a study published online Dec. 5 in Neurology.
Octave Guinebretiere, from Sorbonne Université in Paris, and colleagues examined the association between diseases and symptoms diagnosed in primary care and the risk for MS relative to controls and two other autoimmune inflammatory diseases (lupus and Crohn disease) in a case-control study. The study population included 20,174 patients with MS; 54,790 patients without MS; 30,477 patients with Crohn disease; and 7,337 patients with lupus.
The researchers observed significant positive associations for 12 International Classification of Diseases, 10th Revision (ICD-10) codes with the risk for MS compared with controls without MS. Five codes remained significantly associated with MS after considering ICD-10 codes suggestive of neurological symptoms as the first diagnosis of MS: depression, sexual dysfunction, constipation, cystitis, and urinary tract infections of unspecified site (odds ratios, 1.22, 1.47, 1.50, 1.21, and 1.38, respectively). In comparisons with lupus and Crohn disease, none of these conditions was selectively associated with MS. During the five years after diagnosis, all five ICD-10 codes identified were still associated with MS.
"Due to the frequency of these symptoms in the general population and the nonspecificity regarding prodrome in other autoimmune diseases, we should not expect that the identification of a prodrome will dramatically change clinical care, at least in the general population," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
High-Efficacy Therapy Cuts Disability Progression in Pediatric MS
FRIDAY, April 12, 2024 -- Treatment of pediatric-onset relapsing-remitting multiple sclerosis with high-efficacy therapy reduces the risk for transition across disability states...
AAN: Monoclonal Antibodies for MS During Breastfeeding Not Harmful
TUESDAY, March 12, 2024 -- For mothers with multiple sclerosis or neuromyelitis optica spectrum disease, receipt of monoclonal antibodies (mAb) during breastfeeding is not...
Frexalimab Has Favorable Effect on Relapsing Multiple Sclerosis
WEDNESDAY, Feb. 14, 2024 -- For patients with relapsing multiple sclerosis, the anti-CD40L monoclonal antibody frexalimab has a favorable effect on the number of new...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.